# Risperdal Consta for Bipolar Disorder

> **NCT00177164** · PHASE3 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 50 (actual)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** Injectable Risperidone (Consta) or oral antipsychotic

## Key facts

- **NCT ID:** NCT00177164
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2008-03
- **Final completion:** 2009-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00177164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00177164, "Risperdal Consta for Bipolar Disorder". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00177164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*